Patents by Inventor Yoon-Keun Kim

Yoon-Keun Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240180833
    Abstract: Provided are vesicles derived from bacteria of the genus Paracoccus and a use thereof in which the vesicles efficiently inhibit pathogenic biological factor-induced secretion of inflammatory mediators which induce inflammation, and the vesicles can be advantageously used for the purpose of preparing a composition for preventing, alleviating, or treating inflammatory diseases and be used therefor.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 6, 2024
    Applicant: MD HEALTHCARE INC.
    Inventor: Yoon-Keun KIM
  • Publication number: 20240174045
    Abstract: An air conditioner for a vehicle with an improved structure so that hot air is not directly discharged to a defrost vent in a floor mode or a mix mode, includes an air conditioning case in which an air flow path is formed, and a cooling heat exchanger and a heating heat exchanger provided sequentially on the air flow path of the air conditioning case in an airflow direction, wherein a defrost vent, a face vent, and a floor vent are formed on the air conditioning case, wherein the defrost vent includes a first defogging flow path allowing air passing through the heating heat exchanger to be discharged directly, and a second defogging flow path allowing air passing through the cooling heat exchanger or the heating heat exchanger to be mixed and discharged therethrough.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 30, 2024
    Applicants: Hyundai Motor Company, Kia Corporation, Hanon Systems
    Inventors: Eung Young KIM, Yoon Hyung Lee, Myung Hoe Kim, Seung Ho Lee, Sang Ki Lee, Dae Bok Keon, Yong Sik Kim, Dae Keun Park, Chang Hoon Sung, Hyeon Seok Kim
  • Publication number: 20240174044
    Abstract: An air conditioner for a vehicle capable of preventing a situation in which an occupant's head gets hot by improving a vertical temperature difference between a defrost vent and a floor vent, includes an air conditioning case in which an air flow path is formed, and a cooling heat exchanger and a heating heat exchanger provided sequentially on the air flow path of the air conditioning case in an airflow direction, wherein a defrost vent, a face vent, and a floor vent are formed on the air conditioning case, wherein a hot air duct configured to allow hot air at a downstream side of the heating heat exchanger to flow to an outlet of the floor vent is provided on the air conditioning case.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 30, 2024
    Applicants: Hyundai Motor Company, Kia Corporation, Hanon Systems
    Inventors: Eung Young KIM, Myung Hoe KIM, Yoon Hyung LEE, Seung Ho LEE, Sang Ki LEE, Dae Bok KEON, Dae Keun PARK, Hyeon Seok KIM
  • Publication number: 20240174043
    Abstract: An air conditioner housing of a vehicle includes a body having an internal space through which air flows and having a heat exchanger mounted at the internal space. The heat exchanger cools the air. A discharge port is at a lower end of the body and provides fluid communication between the internal space and an exterior of the body and discharges condensate water generated from the heat exchanger to the exterior. A plurality of blocking portions is disposed around the discharge port and protrudes into the internal space, thereby preventing foreign substances inside the body from directly blocking the discharge port.
    Type: Application
    Filed: July 13, 2023
    Publication date: May 30, 2024
    Applicants: HYUNDAI MOTOR COMPANY, KIA CORPORATION, Hanon Systems
    Inventors: Seung Hoon Moon, Myung Hoe Kim, Yoon Hyung Lee, Seung Ho Lee, Sang Ki Lee, Yong Sik Kim, Dae Bok Keon, Dae Keun Park
  • Patent number: 11992509
    Abstract: Provided is a method for alleviating, preventing or treating a neurodevelopmental disease, neurologic disease, or psychiatric disease, comprising administering to a subject in need thereof a composition including, as an active ingredient, vesicle derived from Micrococcus luteus, wherein the disease including Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis, Huntington's disease, epilepsy, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, autism spectrum disorder, attention deficit hyperactivity syndrome, major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder, dissociative disorders, eating disorders, substance use disorder, and personality disorders occurring as a result of neurogenesis dysfunction or neuroinflammation.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: May 28, 2024
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Publication number: 20240144158
    Abstract: A control apparatus for automating teaching between a gas cylinder transport apparatus and a gas cylinder storage apparatus and a logistics system including the control apparatus are provided. The logistics system includes: a gas cylinder transport apparatus transferring gas cylinders containing process gases; a gas cylinder storage apparatus storing the gas cylinders; and a control apparatus controlling the gas cylinder transport apparatus and the gas cylinder storage apparatus, wherein the control apparatus performs auto-teaching for operations between the gas cylinder transport apparatus and the gas cylinder storage apparatus.
    Type: Application
    Filed: October 27, 2023
    Publication date: May 2, 2024
    Inventors: Yoon Whoi KIM, Seung Jun Lee, Ji Keun Song
  • Patent number: 11970493
    Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: April 30, 2024
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
  • Patent number: 11944652
    Abstract: The present invention relates to vesicles derived from bacteria of the genus Sphingomonas and a use thereof. These vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals. Administration of isolated vesicles suppressed secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles. Upon oral administration, the vesicles were distributed in the brain tissue. Vesicles derived from bacteria of the genus Sphingomonas are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: April 2, 2024
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Publication number: 20240066077
    Abstract: Provided is a method for ameliorating, preventing or treating neutrophilic pulmonary diseases, by administering a composition comprising Micrococcus luteus-derived vesicles as an active ingredient, the composition being capable of effectively treating a neutrophilic pulmonary disease mediated by a nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome (NLRP3 inflammasome).
    Type: Application
    Filed: November 3, 2021
    Publication date: February 29, 2024
    Applicant: MD HEALTHCARE INC.
    Inventor: Yoon-Keun KIM
  • Patent number: 11912674
    Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: February 27, 2024
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
  • Publication number: 20240058393
    Abstract: Provided is Micrococcus luteus-derived extracellular vesicles and a use thereof and, more particularly, to a composition including Micrococcus luteus-derived extracellular vesicles as an active ingredient for alleviation, prevention, or treatment of metabolic diseases, wherein the composition can effectively treat metabolic diseases occurring as a result of a metabolism disorder, including: metabolic cardiovascular diseases such as metabolic syndrome, arteriosclerosis, stroke, and cardiac failure; metabolic liver diseases such as non-alcoholic steatohepatitis and hepatocirrhosis; metabolic renal diseases such as diabetic nephropathy, hypertensive nephropathy, and renal failure; and metabolic musculoskeletal disorders such as gout, sarcopenia, and osteoporosis.
    Type: Application
    Filed: November 15, 2021
    Publication date: February 22, 2024
    Applicant: MD HEALTHCARE INC.
    Inventor: Yoon-Keun KIM
  • Patent number: 11898156
    Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cance
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: February 13, 2024
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Publication number: 20240033303
    Abstract: Provided is a use for preventing and treating neurological diseases or psychiatric diseases, including vesicles derived from Sphingomonas bacteria. The vesicles derived from Sphingomonas bacteria according to the presently claimed subject matter ameliorate symptoms caused by brain damage, such as memory ability and spatial perception ability, when administered to a brain disease mouse model, and therefore, are expected to be usefully used as a composition for preventing, alleviating or treating neurological diseases or psychiatric diseases.
    Type: Application
    Filed: November 16, 2021
    Publication date: February 1, 2024
    Applicant: MD HEALTHCARE INC.
    Inventor: Yoon-Keun KIM
  • Patent number: 11883440
    Abstract: Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: January 30, 2024
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Publication number: 20240009255
    Abstract: Provided is a composition for preventing, treating or alleviating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases, comprising Lactococcus lactis-derived vesicles, and it was confirmed that, when Lactococcus lactis-derived vesicles according to the presently claimed subject matter were administered to a Th2 hypersensitivity immune disease mouse model, the vesicles inhibited eosinophilic inflammation and the consequent functional and histopathological changes. It was also confirmed that the vesicles inhibited the secretion of Th2 cytokines such as IL-5 and IL-13 in T cells of the Th2 hypersensitivity immune disease mouse model, which is shown by inducing IL-12 secretion that suppresses a Th2 immune response in dendritic cells, which are antigen-presenting cells.
    Type: Application
    Filed: October 19, 2021
    Publication date: January 11, 2024
    Applicant: MD HEALTHCARE INC.
    Inventor: Yoon-Keun KIM
  • Patent number: 11827939
    Abstract: The present invention relates to a method of diagnosing cholangiocarcinoma through bacterial metagenomic analysis, and more particularly to a method of diagnosing cholangiocarcinoma by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using subject-derived samples. Extracellular vesicles secreted from bacteria present in the environment are absorbed into the body, and can directly affect the occurrence of cancer, and cholangiocarcinoma is difficult to diagnose early before symptoms appear so that effective treatment is difficult.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: November 28, 2023
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 11771742
    Abstract: The present invention relates to vesicles derived from bacteria belonging to the genus Cupriavidus and a use thereof, the vesicles derived from bacteria belonging to the genus Cupriavidus may be usefully used for the purpose of developing a method of diagnosing a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, or depression, and a composition for preventing or treating the diseases.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: October 3, 2023
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Publication number: 20230287517
    Abstract: The present invention relates to vesicles derived from bacteria of the genus Collinsella and a use thereof. The inventors experimentally confirmed that the vesicles significantly decreased in a clinical sample obtained from a patient with gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, chronic obstructive pulmonary disease (COPD), diabetes, mild cognitive impairment or Alzheimer’s disease, compared with a normal person, and when the vesicles isolated from the strain were administered, the secretion of inflammation mediators caused by pathogenic vesicles such as E.
    Type: Application
    Filed: March 5, 2019
    Publication date: September 14, 2023
    Inventor: Yoon-Keun Kim
  • Publication number: 20230256040
    Abstract: Provided are a method for preventing, improving, or treating a neurological disorder, mental disorder, senescence, or symptoms thereof, comprising administering to a subject in need thereof vesicles derived from Lactobacillus paracasei as an active ingredient, and a pharmaceutical or functional food composition comprising the vesicles
    Type: Application
    Filed: April 25, 2023
    Publication date: August 17, 2023
    Applicant: MD HEALTHCARE INC.
    Inventor: Yoon-Keun KIM
  • Patent number: D1025970
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: May 7, 2024
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yoon-Young Kim, Yun-Su Cho, Hyun-Keun Son, Bum-Soo Park